Loading
DarioHealth Corp. Stock: price and insider trades · United States
1 insider bought €88k of shares over the last 90 days, the latest by Matheis Dennis, filed 28 Jul 2026.
DarioHealth Corp.: what insiders have been doing
This page follows insider dealings at DarioHealth Corp. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. From 22 October 2025 to 22 October 2026, the disclosure feed for DarioHealth Corp. logged 14 filings by 8 insiders.
The flow runs one way only: 1 insider bought (1 purchase totalling €88k) and nobody sold on the market. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 senior executive. Matheis Dennis filed the largest purchase, €88k, on 28 July 2026, which represents 0.15% of the company's market value.
With 14 filings in twelve months, the company is quieter than the median of 24 filings across the 3,171 companies we follow on the same exchange. Looking back to 2016, when coverage begins, insiders filed 103 purchases and 19 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 22.4 m USD and net income at -41.7 m USD.
The last purchase on record was published on 28 July 2026, which is 88 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
359
Thresholds
n/a
Buy Volume
€836,775
103 ops. · all time
Sell Volume
€3M
19 ops. · all time
Who traded when
BuySaleSteven Charles Nelson2 buys
Dennis Matheis1 buy
Since the insiders bought
- -48.6%Entry US$7.10 · Close 21 Oct 2026 US$3.65
- -33.5%Entry US$10.18 · Close at T+365 US$6.77
- -41.3%Entry US$16.20 · Close at T+365 US$9.51
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate DarioHealth Corp. Strong Buy (bullish), based on 5 analysts. Average price target: US$13.60.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,649 of 26,250 companies
21.7
score / 100
Value2
Quality42
FCF yld-65%
Earn yld-154%
EV/EBITDA·
ROE-60%
Gross mgn57%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.08
Analyst consensus
5 analystsStrong buy
US$8.00Target US$13.60(+233%)US$28.00
Income statement
RevenueUS$22.4M
Gross profitUS$12.7M57% margin
EBITDA-US$35.5M-159% margin
Net income-US$61.7M-169.9% margin
Valuation
PER (forward)-3.6x
P/Book0.5x
Beta1.18
Balance sheet & cash
Market capUS$40M
Total debtUS$31.7M
Free Cash Flow-US$26.1M
Debt / Equity59%
Profitability & ownership
ROE-59.9%
ROA-19.4%
% insiders21.7%
% institutions9.1%
Last declaration on 28 September 2026
Declarations359 total
28,000 shares0Common StockSEC:0001104659-26-111346:0
54,000 shares0Common StockSEC:0001104659-26-111349:1
11,760 shares@ US$40.40Common StockSEC:0001104659-26-111351:0
62,000 shares0Common stockSEC:0001104659-26-111353:0
579 shares@ US$19.10Common StockSEC:0001104659-26-111343:0
297,000 shares0Common StockSEC:0001104659-26-111343:1
44,000 shares0Common StockSEC:0001104659-26-111347:0
95,000 shares0Common StockSEC:0001104659-26-111348:0
772 shares@ US$19.10Common StockSEC:0001104659-26-111349:0
61,000 shares0Common StockSEC:0001104659-26-111350:0
8,435 shares@ US$16.60Common StockSEC:0001104659-26-111351:1
28,000 shares0Common StockSEC:0001104659-26-111351:2
965 shares@ US$19.1016.1% of flowCommon StockSEC:0001104659-26-087626:0
14,430 shares@ US$6.930.15% mcap100.0% of flowCommon StockSEC:0001104659-26-087626:1
Canonical exit: 21 Oct 2026 (T+90)
20,000 shares0Common StockSEC:0001104659-25-090007:0
60,000 shares0Common StockSEC:0001104659-25-090006:0
30,000 shares0Common StockSEC:0001104659-25-090098:0
20,000 shares0Common StockSEC:0001104659-25-090097:0
20,000 shares0Common StockSEC:0001104659-25-090019:0
5,000 shares0Common StockSEC:0001104659-25-090004:0
20,000 shares0Common StockSEC:0001104659-25-090002:0
20,000 shares0Common StockSEC:0001104659-25-089997:0
20,000 shares0Common StockSEC:0001104659-25-089996:0
40,000 shares@ US$0.5347.5% of flowCommon StockSEC:0001104659-25-084035:0
Canonical exit: 25 Nov 2025 (T+90)
500,000 shares0Common StockSEC:0001104659-25-049388:0
25 of 359 declarations
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a U.S.-listed digital health company traded on the NASDAQ market in the United States. Founded in 2011, the business originally grew out of a direct-to-consumer model and has since evolved toward a broader B2B2C strategy serving employers, health plans, pharmaceutical partners, providers, and consumers. Its operating headquarters is in New York, with parts of its technology and corporate history tied to Israel through subsidiary operations. ([dariohealth.com](https://www.dariohealth.com/articles/a-different-approach-to-health-care/?utm_source=openai))
DarioHealth’s core proposition is an integrated digital platform for chronic-condition management and whole-person care. The company positions itself as consumer-led and clinically driven, combining mobile tools, connected devices, coaching, behavioral support, and data-driven engagement. Its main solution areas now span cardiometabolic care, including diabetes, hypertension, obesity, and GLP-1 support, as well as musculoskeletal care and behavioral health. The platform is designed to improve adherence, deepen member engagement, and support measurable clinical and economic outcomes for commercial partners. ([dariohealth.com](https://www.dariohealth.com/?utm_source=openai))
Read moreShow less
From a competitive standpoint, DarioHealth operates in a crowded digital health market where differentiation depends on user retention, clinical evidence, multi-condition breadth, and the ability to sell into employer and payer channels. The acquisition of Twill materially expanded the product set by adding behavioral health and navigation capabilities, and management highlighted the full integration of those capabilities in 2024 as a step toward a more comprehensive end-to-end platform. The company’s competitive message is increasingly centered on being a multi-condition platform rather than a single-condition point solution. ([dariohealth.com](https://www.dariohealth.com/pressreleases/dario-announces-integration-twill-capabilities-across-full-platform/?lang=es&utm_source=openai))
Recent milestones point to a commercial acceleration strategy. In January 2025, DarioHealth announced a collaboration with MediOrbis to add prescribing capabilities to its GLP-1 behavior-change solution, broadening its medical weight-loss offering and supporting both employer and direct-to-consumer use cases. During 2024, the company also announced a commercial reorganization aimed at streamlining leadership and speeding revenue growth, while reporting stronger momentum in its core B2B2C channel. For investors, DarioHealth remains a small-cap growth name in healthcare technology: the opportunity is tied to platform expansion and commercial execution, while the risk profile still reflects intense competition and ongoing funding needs. ([dariohealth.com](https://www.dariohealth.com/pressreleases/dariohealth-expands-glp-1-solution-prescribing-capabilities-partnership-mediorbis-targeting-employers-d2c-markets/?utm_source=openai))
